ATE195149T1 - Protein-antagonisten der blut-koagulation und ihre verwendung - Google Patents

Protein-antagonisten der blut-koagulation und ihre verwendung

Info

Publication number
ATE195149T1
ATE195149T1 AT91920567T AT91920567T ATE195149T1 AT E195149 T1 ATE195149 T1 AT E195149T1 AT 91920567 T AT91920567 T AT 91920567T AT 91920567 T AT91920567 T AT 91920567T AT E195149 T1 ATE195149 T1 AT E195149T1
Authority
AT
Austria
Prior art keywords
viia
factors vii
factor
complex
protein antagonists
Prior art date
Application number
AT91920567T
Other languages
English (en)
Inventor
Howard R Soule
Terence K Brunck
Original Assignee
Corvas Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corvas Int Inc filed Critical Corvas Int Inc
Application granted granted Critical
Publication of ATE195149T1 publication Critical patent/ATE195149T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT91920567T 1990-10-22 1991-10-17 Protein-antagonisten der blut-koagulation und ihre verwendung ATE195149T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60145490A 1990-10-22 1990-10-22
US07/759,443 US5506134A (en) 1990-10-22 1991-09-13 Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
PCT/US1991/007811 WO1992006711A1 (en) 1990-10-22 1991-10-17 Blood coagulation protein antagonists and uses therefor

Publications (1)

Publication Number Publication Date
ATE195149T1 true ATE195149T1 (de) 2000-08-15

Family

ID=27083860

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91920567T ATE195149T1 (de) 1990-10-22 1991-10-17 Protein-antagonisten der blut-koagulation und ihre verwendung

Country Status (9)

Country Link
US (1) US5506134A (de)
EP (1) EP0554383B1 (de)
JP (1) JP2680192B2 (de)
AT (1) ATE195149T1 (de)
AU (1) AU654311B2 (de)
CA (1) CA2094372A1 (de)
DE (1) DE69132352T2 (de)
ES (1) ES2151880T3 (de)
WO (1) WO1992006711A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
WO1995017907A1 (en) * 1993-12-27 1995-07-06 Hamilton Civic Hospitals Research Development, Inc. Methods and compositions for inhibiting thrombogenesis
US5683899A (en) * 1994-02-03 1997-11-04 University Of Hawaii Methods and compositions for combinatorial-based discovery of new multimeric molecules
DE19802139C1 (de) * 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
EP0987274A1 (de) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Faktor VIIa Inhibitore
EP1131091B1 (de) * 1998-11-20 2003-04-02 Eli Lilly And Company Behandlung von hämorrhagischem virusfieber mit protein c
EP1059302A1 (de) 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Faktor VIIa Inhibitore
EP1095933A1 (de) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH N-Guanidinoalkylamide, Verfahren zu ihrer Herstellung, ihre Verwendung und pharmazeutische Zusammensetzungen, die sie enthalten
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
EP1162194A1 (de) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Auf Faktor VIIa inhibitorisch wirkende (Thio)-Harnstoff Verbindungen, Verfahren zu deren Herstellung und deren Verwendung
AU3320602A (en) 2000-12-06 2002-06-18 Aventis Pharma Gmbh Guanidine and amidine derivatives as factor xa inhibitors
AU2002221099A1 (en) * 2000-12-08 2002-06-18 Takeda Chemical Industries Ltd. Combination drugs
AU2002240000A1 (en) * 2001-01-23 2002-08-06 Saint Louis University Factor ixa: factor viiia interaction and methods therefor
EP1260817A3 (de) 2001-05-08 2002-12-18 Warner-Lambert Company Methode zur Direktbestimmung von Koagulationsfaktor VIIa in Plasma
EP1270551A1 (de) 2001-06-26 2003-01-02 Aventis Pharma Deutschland GmbH Harnstoffverbindungen mit antiproteolytischer Wirkung
ES2407355T3 (es) * 2001-07-03 2013-06-12 Oklahoma Medical Research Foundation Ensayo para medir los complejos de factor VIIa-antitrombina
CA2463655A1 (en) 2001-10-15 2003-04-24 Chiron Corporation Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
WO2003039585A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
EP1314733A1 (de) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indol-2-carbonsäureamide als Faktor-Xa-Hemmer
US20040126856A1 (en) * 2002-01-23 2004-07-01 Bajaj Paul S. Factor ixa: factor Vllla interaction and methods therefor
AU2003206571A1 (en) * 2002-02-22 2003-09-09 Prophy Med Ab Use of an inhibitor or antagonist against tissue factor
US6706068B2 (en) 2002-04-23 2004-03-16 Bret A. Ferree Artificial disc replacements with natural kinematics
KR101080587B1 (ko) * 2002-05-01 2011-11-04 바이엘 파마 악티엔게젤샤프트 항응고제로서의 신규 조직 인자 표적화된 항체
US7579000B2 (en) * 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
US20040110929A1 (en) * 2002-07-12 2004-06-10 Bjorn Soren E. TF binding compound
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
EP1479675A1 (de) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazolderivate als Faktor Xa-Inhibitoren
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
US7317027B2 (en) 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
EP1479677A1 (de) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Neue Indolderivate als Faktor Xa-Inhibitoren
US20060223177A1 (en) 2003-06-27 2006-10-05 Ethicon Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
ES2552226T3 (es) 2003-06-27 2015-11-26 DePuy Synthes Products, Inc. Reparación y regeneración de cartílago y hueso utilizando células derivadas posparto
DE10333508A1 (de) * 2003-07-18 2005-02-17 Technische Universität Dresden Gegen Prothrombin gerichtete Erkennungsmoleküle und die Verwendung dieser
EP1568698A1 (de) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrolderivate als faktor-xa-inhibitoren
BRPI0509776A (pt) * 2004-04-16 2007-10-23 Scripps Research Inst método de modulação da vascularização em um tecido de um mamìfero
US20110159006A1 (en) * 2008-06-19 2011-06-30 Erik Hack Use of anti-factor xi antibodies for prevention of thrombus formation
AU2011267106B2 (en) 2010-06-15 2015-05-14 Genmab A/S Human antibody drug conjugates against tissue factor
FI2734552T3 (fi) 2011-07-22 2025-02-12 Csl Behring Gmbh Monoklonaaliset anti-tekijä xii/xiia -vasta-aineet ja niiden käyttö
US8853154B2 (en) 2012-09-13 2014-10-07 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
CA3099547A1 (en) 2018-05-07 2019-11-14 Reshma Abdulla RANGWALA Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
AU2020259982A1 (en) 2019-04-17 2021-10-28 Novo Nordisk A/S Bispecific antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4382083A (en) * 1981-06-25 1983-05-03 Baxter Travenol Laboratories, Inc. Therapeutic method for treating blood-clotting defects with factor VIIa
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
SE461315B (sv) * 1988-06-16 1990-02-05 Jan Niels Faergemann Anvaendning av en komposition innehaallande aluminiumacetotartrat och en diol foer att minska hudirritationer orsakade av urin eller avfoering, samt bloeja impregnerad med kompositionen
US5190919A (en) * 1989-11-13 1993-03-02 Board Of Regents, The University Of Texas System Antihemostatic factor vii peptides

Also Published As

Publication number Publication date
CA2094372A1 (en) 1992-04-23
DE69132352T2 (de) 2001-03-15
WO1992006711A1 (en) 1992-04-30
ES2151880T3 (es) 2001-01-16
EP0554383A1 (de) 1993-08-11
JP2680192B2 (ja) 1997-11-19
AU654311B2 (en) 1994-11-03
DE69132352D1 (de) 2000-09-07
JPH06502307A (ja) 1994-03-17
EP0554383B1 (de) 2000-08-02
US5506134A (en) 1996-04-09
AU9029891A (en) 1992-05-20
EP0554383A4 (de) 1994-04-27

Similar Documents

Publication Publication Date Title
DE69132352D1 (de) Protein-antagonisten der blut-koagulation und ihre verwendung
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
DE3578578D1 (de) Hirudin-pa und dessen derivate, verfahren zu deren herstellung und deren verwendung.
DK552684A (da) Desulfatohirudiner samt deres fremstilling og anvendelse
ATA260087A (de) Kombination von angiotensin-converting-enzyme- hemmern mit calciumantagonisten sowie ein erzeugnis, das diese enthält, zur anwendung bei der behandlung des bluthochdrucks
DE69510810D1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
ATE429450T1 (de) Chimärische dr4 antikörper und ihre verwendung
DE69434926D1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
DE3785602D1 (de) Verwendung von a-, b- und c-prostaglandinen und deren derivaten zur behandlung von augen-hypertension und glaukom.
ES2110414T3 (es) Derivados de sacarina utiles como inhibidores de enzimas proteoliticas y su preparacion.
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
DE3783966D1 (de) Reagens zur pruefung von periodentalen erkrankungen.
EP1421104A4 (de) Humane zona-pellucida-proteine und verfahren zu deren verwendung bei der diagnose männlicher unfruchtbarkeit
DE69007486D1 (de) Verwendung von calciumantagonisten für die behandlung von narben.
DE59002772D1 (de) Verwendung von Dextransulfat, gegebenenfalls in Kombination mit anti-androgenen Mitteln zur Behandlung des humanen Protatakarzinoms.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE69636367D1 (de) T-pa polymorphismus und dessen verwendung zur risikodiagnose von thrombus assoziierten krankheiten
NO173336C (no) Fremgangsm}te til isolering av basalmembranproteiner fra human- eller animalvev og anvendelse av det oppn}dde protein
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
DE3850933D1 (de) Anticoagulatorisches Protein PP4-X, seine Herstellung und Verwendung.
ES2182356T3 (es) Uso de proteasas de bromelaina para inhibir la coagulacion de la sangre.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties